Ryvu Therapeutics S.A.
RVU.WA · WSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.24 | -0.14 | 0.23 | -0.17 |
| FCF Yield | -3.03% | -3.44% | -6.94% | -3.11% |
| EV / EBITDA | -30.91 | -24.27 | -27.26 | -26.25 |
| Quality | ||||
| ROIC | -16.11% | -13.06% | -15.18% | -14.98% |
| Gross Margin | -191.43% | 72.77% | 78.10% | 77.06% |
| Cash Conversion Ratio | 0.71 | 0.73 | 1.75 | 0.80 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.09% | 3.90% | 12.22% | 25.94% |
| Free Cash Flow Growth | 23.88% | 44.74% | -62.17% | 29.83% |
| Safety | ||||
| Net Debt / EBITDA | 0.64 | 1.19 | 3.30 | 2.76 |
| Interest Coverage | -14.41 | -9.27 | -22.77 | -24.08 |
| Efficiency | ||||
| Inventory Turnover | 70.69 | 5.49 | 3.06 | 4.84 |
| Cash Conversion Cycle | 66.66 | -443.19 | -466.90 | -386.14 |